1,497
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Effects of Tiaopi Xiezhuo decoction on constipation and gut dysbiosis in patients with peritoneal dialysis

, , , , , , , , , & ORCID Icon show all
Pages 531-540 | Received 18 Apr 2022, Accepted 12 Mar 2023, Published online: 30 Mar 2023
 

Abstract

Context

A Chinese herbal formula, Tiaopi Xiezhuo decoction (TXD), is developed from a classical Chinese prescription Sanhuang Xiexin decoction.

Objective

To investigate the regulatory effect of TXD on gut dysbiosis, as a treatment of constipation in patients with peritoneal dialysis (PD).

Materials and methods

The chemical content of TXD was assessed by high-performance liquid chromatography. A total of 29 PD patients were enrolled and treated with TXD orally (3 g crude drug/each/twice/day) for 3 months. Blood and faecal samples were collected at the beginning and end, to determine the changes in biochemical characteristics and gut microbial composition. The stool conditions were asked to be scored. Additional 30 healthy individuals were recruited as a control for the analysis of gut microbiota.

Results

Although having no significant effects on serum biochemical characteristics, 3-month TXD intervention improved constipation in PD patients: decreased 80% abdominal distention (p < 0.01), increased 2.6-fold sloppy stools (p < 0.05) and eliminated hard stool completely (p < 0.01). The analysis of gut microbiota showed that, compared to the healthy group, the microbial richness was reduced in PD patients. After a 3-month TXD treatment, this reduced richness was raised, and Paraprevotella clara, Lachnospiraceae bacterium 2-146FA, Phascolarctobaterium succinatutens, Lachnospiraceae bacterium 2-1-58FAA, Fusobacterium mortiferum, and Prevotella copri were accumulated in the intestinal flora. Furthermore, the bacterial species enriched by TXD correlated with the improvement of constipation.

Discussion and conclusions

TXD treatment may improve constipation by modulating gut dysbiosis in PD patients. These findings provide data to support the further application of TXD in the adjuvant treatment of PD.

Author contributions

During the research work, Dr Yu Peng, Dr Lei Wang and Dr Xusheng Liu designed the studies; Dr Yu Peng, Tingting Zheng, Xiaoning Xie, Jianfeng Wu, and Lizhe Fu recruited the individuals and collected clinical data; Yang Chen did the analysis of gut microbiota; Dr Lei Wang and Yuting Zeng drafted the manuscript; Fuhua Lu, La Zhang, Dr Yu Peng, Lei Wang and Xusheng Liu revised the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was supported by the National Natural Science Foundation of China [No. 82174308].